In vivo bradykinin B2 receptor activation reduces renal fibrosis

Journal of Clinical Investigation

Volumn 110, Issue 3, 2002, Pages 371-379

  Schanstra, Joost P ^a   Neau, Eric ^a   Drogoz, Pascale ^a   Gomez, Miguel A Arevalo ^b   Novoa, José Miguel Lopez ^b   Calise, Denis ^a   Pecher, Christiane ^a   Bader, Michael ^c   Girolami, Jean Pierre ^a   Bascands, Jean Loup ^a,d  

^a INSERM   (France)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; ICATIBANT;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; KALLIKREIN KININ SYSTEM; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY PROXIMAL TUBULE; MALE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RAT;

EID: 0036324650     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0215493     Document Type: Article

References (39)

1. Progression in renal disease
2. Obstructive nephropathy
3. Tubulointerstitial changes as a major determinant in the progression of renal damage
4. Therapeutic approaches in obstructive uropathy
5. Unilateral ureteral obstruction in neonatal rats leads to renal insufficiency in adulthood
6. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction
7. Enalapril reduces collagen IV synthesis and expansion of the interstitium in the obstructed rat kidney
8. Angiotensin I converting enzyme and the changes in our concepts through the years
9. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II)
10. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides
11. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
12. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
13. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The losartan heart failure survival study ELITE II
14. Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons
15. Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene
16. Induction of functional bradykinin B1-receptors in normotensive rats and mice under chronic angiotensin converting enzyme inhibitor treatment
17. Mouse proximal tubular cell-cell adhesion inhibits apoptosis by a cadherin-dependent mechanism
18. The B1-agonist [des-Arg10]-kallidin activates transcription factor NF-κB and induces homologous upregulation of the bradykinin B1-receptor in cultured human lung fibroblasts
19. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis
20. Tissue plasminogen activator release in vivo in response to vasoactive agents
21. Kallikreins and kinins
22. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
23. Are angiotensin II receptor blockers superior to angiotensin converting enzyme inhibitors with regard to their renoprotective effect?
24. Bradykinin-mediated cardiovascular protective actions of ACE-inhibitors
25. Upregulation of renin-angiotensin system and downregulation of kallikrein in obstructive nephropathy
26. Mechanisms by which bradykinin promotes fibrosis in vascular sooth muscle cells: Role of TGF-β and MAPK
27. Regulation of cardiac fibroblast extracellular matrix production by bradykinin and nitric oxide
28. Bradykinin stimulates tissue plasminogen activator release in human vasculature
29. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathways
30. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling
31. Structure of human pro-matrix metalloproteinase-2: Activation mechanism revealed
32. Loss of glomerular function and tubulointerstitial fibrosis: Cause or effect?
33. Immunological aspects of acute ureteral obstruction: Immune cell infiltrate in the kidney
34. Bradykinin receptor antagonists
35. Bradykinin stimulates lung fibroblasts to release neutrophil and monocyte chemotactic activity
36. Renal interstitial fibrosis is reduced in angiotensin II type 1a receptor deficient mice
37. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ligation
38. Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis
39. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction